Ixabepilone, First in a New Class of Antineoplastic Agents: The Natural Epothilones and Their Analogues-Reference-Cited by-同舟云学术

Ixabepilone, First in a New Class of Antineoplastic Agents: The Natural Epothilones and Their Analogues

Published:2007-10 Issue:10 Volume:7 Page:9-15
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Fornier Monica N.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer;Thompson;Proc Am Soc Clin Oncol,2003

2. Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer;Østerlind;J Clin Oncol,2005

3. A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results;Buzdar;Breast Cancer Res Treat,2005

4. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer;Overmoyer;J Clin Oncol,2005

5. Molecular mechanisms of drug resistance;Longley;J Pathol,2005

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SPC-180002, a SIRT1/3 dual inhibitor, impairs mitochondrial function and redox homeostasis and represents an antitumor activity;Free Radical Biology and Medicine;2023-11

2. Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance;Frontiers in Oncology;2020-06-02

3. Editorial for Cancer Virtual Issue;ACS Medicinal Chemistry Letters;2017-12-14

4. Agents Targeting Microtubules and Mitotic Processes;Holland‐Frei Cancer Medicine;2017-02-26

5. Ixabepilone for the treatment of endometrial cancer;Expert Opinion on Investigational Drugs;2016-03-24